Psoriatic Arthritis Patients are at Higher Risk for Cardiovascular Disease

Psoriatic Arthritis Patients are at Higher Risk for Cardiovascular Disease

By Spondylitis Association of America

New evidence, presented by Alexander Egeberg, MD, PhD, University of Copenhagen, and colleagues in the Journal of the American Academy of Dermatology suggests that patients with psoriasis or any related form of the condition, such as psoriatic arthritis, have a higher risk of experiencing a cardiovascular disease event (CVD) compared to non-afflicted individuals.

Risks of NSAID Toxicity May Differ Between Medications

Risks of NSAID Toxicity May Differ Between Medications

By Spondylitis Association of America

Chances are, if you are living with spondyloarthritis, you have taken Non-Steroidal Anti-Inflammatory Drugs (NSAIDs,) as they are the most widely used class of medications for spondyloarthritis symptom relief. You are also likely aware that all NSAIDs carry some risk of major toxicity. A recent study now suggests that some NSAIDs carry higher risks for older adults who take NSAIDs regularly.   

Shingles Vaccine is Now Available to Those on Biologic Medications

Shingles Vaccine is Now Available to Those on Biologic Medications

By Spondylitis Association of America

Biologic medications can play an important role for those living with spondyloarthritis. They may slow the progression of the disease, treat joint/spinal arthritic pain, and can generally alleviate many symptoms. However, like all medications, they have drawbacks for those taking them - one being that patients on biologics can’t receive live vaccines - including, until very recently, the Shingles vaccine.

FDA Approves SIMPONI ARIA for Ankylosing Spondylitis and Psoriatic Arthritis

By Spondylitis Association of America

On October 20th, 2017 Janssen Biotech, Inc. announced that the FDA has approved SIMPONI ARIA (IV administered golimumab) for the treatment of adults with active ankylosing spondylitis (AS) or active psoriatic arthritis (PsA.)

The Correlation Between BMI and TNF Inhibitor Response in Ankylosing Spondylitis

The Correlation Between BMI and TNF Inhibitor Response in Ankylosing Spondylitis

By Spondylitis Association of America

One of the larger challenges involved in treating ankylosing spondylitis (AS) is the varying effects of, and responses to, available medications. Currently, Tumor Necrosis Factors (TNF) inhibitors are the standard of care for most patients with moderate to severe AS, and, as with any form of organic medication, their effectiveness can be influenced by various biological factors.

RSS
12345678

Stay Informed

Contact Us

Spondylitis Association of America

16360 Roscoe Blvd.  Ste. 100
Van Nuys, CA 91406

Email

info@spondylitis.org

Toll Free Hotline

(800) 777-8189 U.S. only
or (818) 892-1616

Give With Confidence

Independent Charities of America